Genet ics Analysis of Polymorphic Patterns in Candidate Genes in Israeli Patients with Prostate Cancer
暂无分享,去创建一个
E. Friedman | A. Figer | J. Baniel | D. Flex | A. Sidi | A. E. Manguoğlu | T. Tichler | T. Friedman | I. Novikov | A. Vazina | E. E. Sapir | Avi Shtrieker
[1] M. Marberger,et al. Vitamin D receptor gene polymorphism and prostate cancer risk , 2002, The Prostate.
[2] J. Stanford,et al. A polymorphism in the CYP17 gene and risk of prostate cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[3] K. Klinger,et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1 , 2002, Nature Genetics.
[4] T. Beer,et al. Association of codon 72 polymorphism of p53 with lower prostate cancer risk , 2001, The Prostate.
[5] R. Eeles,et al. Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer. , 2001, Pharmacogenetics.
[6] J. Trachtenberg,et al. HPC2 variants and screen-detected prostate cancer. , 2001, American journal of human genetics.
[7] J. Carpten,et al. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. , 2001, American journal of human genetics.
[8] B. Green,et al. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. , 2000, Pharmacogenetics.
[9] T. Rebbeck,et al. Association of HPC2/ELAC2 genotypes and prostate cancer. , 2000, American journal of human genetics.
[10] E. Goode,et al. Analysis of chromosome 1q42.2-43 in 152 families with high risk of prostate cancer. , 1999, American journal of human genetics.
[11] D. Grignon,et al. p53 gene alterations in prostate cancer after radiation failure and their association with clinical outcome: a molecular and immunohistochemical analysis. , 1999, Pathology, research and practice.
[12] Taylor Murray,et al. Cancer statistics, 1999 , 1999, CA: a cancer journal for clinicians.
[13] P. Lin,et al. p53 codon 72 polymorphism in Taiwanese lung cancer patients: association with lung cancer susceptibility and prognosis. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] F. Oesch,et al. Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfotransferases: influence on cancer susceptibility. , 1998, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.
[15] D. Forman,et al. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. , 1997, Carcinogenesis.
[16] B. Riggs. Vitamin D-receptor genotypes and bone density. , 1997, The New England journal of medicine.
[17] S. Shapiro,et al. Family history and prostate cancer risk. , 1996, American journal of epidemiology.
[18] Jack A. Taylor,et al. Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer , 1996, Molecular carcinogenesis.
[19] J. Mohler,et al. Association of prostate cancer with vitamin D receptor gene polymorphism. , 1996, Cancer research.
[20] R. Weaver,et al. The immunohistochemical localization of drug‐metabolizing enzymes in prostate cancer , 1995, The Journal of pathology.
[21] S. Anttila,et al. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility--a review. , 1995, Gene.
[22] J. S. Sidhu,et al. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. , 1994, Human molecular genetics.